Clinically and pharmacologically relevant interactions of antidiabetic drugs.
Article Details
- CitationCopy to clipboard
May M, Schindler C
Clinically and pharmacologically relevant interactions of antidiabetic drugs.
Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83. doi: 10.1177/2042018816638050. Epub 2016 Mar 31.
- PubMed ID
- 27092232 [ View in PubMed]
- Abstract
Patients with type 2 diabetes mellitus often require multifactorial pharmacological treatment due to different comorbidities. An increasing number of concomitantly taken medications elevate the risk of the patient experiencing adverse drug effects or drug interactions. Drug interactions can be divided into pharmacokinetic and pharmacodynamic interactions affecting cytochrome (CYP) enzymes, absorption properties, transporter activities and receptor affinities. Furthermore, nutrition, herbal supplements, patient's age and gender are of clinical importance. Relevant drug interactions are predominantly related to sulfonylureas, thiazolidinediones and glinides. Although metformin has a very low interaction potential, caution is advised when drugs that impair renal function are used concomitantly. With the exception of saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitors also show a low interaction potential, but all drugs affecting the drug transporter P-glycoprotein should be used with caution. Incretin mimetics and sodium-glucose cotransporter-2 (SGLT-2) inhibitors comprise a very low interaction potential and are therefore recommended as an ideal combination partner from the clinical-pharmacologic point of view.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Acetohexamide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Carbutamide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Gliquidone Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Glisoxepide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails Tolazamide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails - Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Pyrimethamine Multidrug and toxin extrusion protein 1 Protein Humans NoInhibitorDetails Pyrimethamine Multidrug and toxin extrusion protein 2 Protein Humans NoInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAcarboseMoxifloxacin The therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin. AcarboseGrepafloxacin The therapeutic efficacy of Acarbose can be increased when used in combination with Grepafloxacin. AcarboseEnoxacin The therapeutic efficacy of Acarbose can be increased when used in combination with Enoxacin. AcarbosePefloxacin The therapeutic efficacy of Acarbose can be increased when used in combination with Pefloxacin. AcarboseCiprofloxacin The therapeutic efficacy of Acarbose can be increased when used in combination with Ciprofloxacin.